Topics The 21st Pharmaceutical Association of Japan Forum held
The "Pharmaceutical Manufacturers Association of Japan (PMAJ) Forum" is held once a year to deepen understanding of the pharmaceutical industry by bringing together representatives of various industries closely related to the pharmaceutical industry and representatives of member companies for a frank exchange of opinions. In 2022, the 21st Pharmaceutical Association Forum was held on November 24 at Keidanren Kaikan (Chiyoda-ku, Tokyo). This year, we asked Mr. Yoshinao Mishima, President of the Japan Agency for Medical Research and Development (AMED), to deliver a lecture. Following opening remarks by Yasushi Okada, Chairman of the Pharmaceutical Manufacturers Association of Japan (PMAJ), the following lectures were given.
The venue
AMED's efforts to promote R&D in the health and medical fields
Yoshinao Mishima, President, Japan Agency for Medical Research and Development (AMED)
AMED has been working to promote consistent research and development in the medical field, from basic to practical application, and to put the results to practical use, as well as to improve the environment for smooth and effective research and development, aiming to "put the results to practical use and deliver them to patients and their families as soon as possible". Currently, under the second phase of the Health and Medical Care Strategy, which started in FY2020, six "integrated projects" have been defined, focusing on modalities, etc. Under the leadership of the program director (PD), projects of related ministries and agencies are coordinated and promoted in an integrated manner from basic to practical applications. In addition, PDs, Program Supervisors (PSs), and Program Officers (POs) are appointed as experts who have excellent academic experience and track records in research and development, as well as insight into the evaluation of R&D projects and business operations, to promote R&D in the medical field with consistent management functions. The PDs, Program Supervisors (PSs), and Program Officers (POs) are experts in the evaluation of research and development projects and business operations.
In particular, in order to promote the practical application of pharmaceuticals, it is important to conduct research and development that takes into account the characteristics and properties of the modality in collaboration with universities and industry, from the search for drug targets to clinical research. For this reason, AMED promotes fundamental research and development and regulatory science related to modalities, centered on pharmaceutical projects, to utilize innovative seeds generated in academia and other fields, and to create new drugs by utilizing technologies and knowledge related to various modalities in a cross-disease manner. In addition, we aim to create new drugs by utilizing technologies and knowledge related to various modalities in a cross-disease manner. In addition, we are working to build the necessary support infrastructure for drug discovery research and development, including the sharing of drug design technologies, compound libraries, and analytical equipment.
In addition, for the urgent issue of novel coronavirus infection (COVID-19), we have actively supported various research projects, including basic research to elucidate the pathogenesis, practical application of technologies related to diagnosis and treatment, and development of therapeutic drugs and vaccines. Based on the "Strategy for Strengthening the Vaccine Development and Production System" (approved by the Cabinet in June 2021), the measures necessary to build a system that enables rapid development and supply of vaccines include "formation of a world-class vaccine R&D center," "enhancement and acceleration of domestic and overseas clinical trials," "acceleration of the pharmaceutical approval process and improvement of standards," "drug discovery We are also working to raise the level of the drug discovery venture ecosystem. Furthermore, in March 2022, the Center for Advanced Research and Development Strategies (SCARDA) was established within the AMED to engage in strategic funding of research expenses, and has already adopted issues such as a coronavirus vaccine in anticipation of the next pandemic.
Lecture Scene
(Executive Director: Tokio Inoguchi )